RE:RE:RE:RE:RE:RE:RE:FDA Clears Peptide-Drug Conjugate for RRMM Apart from the structure it's got a very odd mechanism of action. Looks like it relies on the first 10mins after injection for the PDC to enter all cells but be preferentially be toxic to cancer cells, after that time the PDC is all cleaved in the blood and can enter every cell as parent chemo where it is toxic to every cell, that must be why they have the neutropenia. Once they do head-to-head trials might show it doesn't really have any benefit over existing chemo. It has a very tightly defined label, must be r/r for 3 other drug types, my guess is there are doubts whether it really brings added benefit but it clearly has some anti-tumour activity. It's not really a targeted drug in that it's designed to pass thru the membrane of all cells, it's 'targeting' is in that once in the cell it's only metabolized in certain cancer cells but that benefit seems to be lost/reduced given so much of it is cleaved in the blood.
It has a label that reminds me of Trogarzo in that the label seems designed to make it that last ditch chance, the difference being clinically Trogarzo has a clear clinical rationale and good (but limited) efficacy data.
scarlet1967 wrote: I won't look into it again take your word for it.